Oppenheimer analyst Jay Olson downgrades Sierra Oncology (NASDAQ:SRRA) from Outperform to Perform and raises the price target from $45 to $55.
Oppenheimer Downgrades Sierra Oncology to Perform, Raises Price Target to $55
Oppenheimer analyst Jay Olson downgrades Sierra Oncology (NASDAQ:SRRA) from Outperform to Perform and raises the price target from $45 to $55.
Related Posts
Genie Energy Q2 EPS $0.19 Up From $0.06 YoY, Sales $97.70M Up From $76.08M YoY
Genie Energy (NYSE:GNE) reported quarterly earnings of $0.19 per share. This is a 216.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported $97.70 million in sales
Unrivaled Brands Sells Inoperative Property For $13.4M In Effort To Become Cash Flow Positive
Cannabis company Unrivaled Brands, Inc. (OTCQX: UNRV) confirmed Monday it will sell its real property and building located on Dyer Road in Santa Ana, California for $13.4 million. The sale is expected to close in January 2022, and the company will retire $9.0 million of outstanding debt on t